Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: LISA A JACKSON
Organization: KAISER FOUNDATION RESEARCH INSTITUTE
Fiscal Year: 2022
Award: $2,114,527
Funding agency: National Institute of Allergy and Infectious Diseases

The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during
pregnancy or postpartum. The Seattle Children’s Research Institute, a subcontractor to the Kaiser Washington
VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The
NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the
Seattle Children’s Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for
the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.

Terms: <0-11 years old><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Assay><Bioassay><Biologic Assays><Biological Assay><COVID-19 vaccine><COVID-19 virus><COVID19 vaccine><COVID19 virus><Child><Child Youth><Children (0-21)><CoV-2><CoV2><Evaluation><Funding><Gestation><NIH><National Institutes of Health><Postpartum><Postpartum Period><Pregnancy><Protocol><Protocols documentation><Research Institute><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><United States National Institutes of Health><Vaccines><Washington><Work><Wuhan coronavirus><clinical research site><clinical site><corona virus disease 2019 vaccine><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><hCoV19><immunogenicity><nCoV2><post-partum><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><youngster>